Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trialJohn A. Smith, Sean Parker, Michael M. Kitt et al.|The Lancet Respiratory Medicine|2020Cited by 224
No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac DiseaseJoseph A. Murray, Richard A. Krause, Tsung‐Teh Wu et al.|Gastroenterology|2016Cited by 137